How to Treat Autoimmune Liver Disease

Autoimmune liver diseases represent a group of chronic inflammatory conditions in which the body’s immune system mistakenly attacks hepatocytes and bile ducts. The three primary forms include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). While their underlying mechanisms differ, all involve dysregulated immune responses leading to progressive hepatic injury, fibrosis, and—without intervention—potential cirrhosis or liver failure.

Treatment strategies are highly individualized and depend on the specific diagnosis, disease stage, severity of inflammation or cholestasis, and presence of complications. For autoimmune hepatitis, first-line therapy typically consists of corticosteroids—most commonly prednisone or budesonide—combined with azathioprine to induce remission. Maintenance therapy aims to minimize steroid exposure while sustaining biochemical and histological control; some patients may eventually taper to monotherapy with azathioprine or transition to alternatives like mycophenolate mofetil if intolerance or nonresponse occurs.

In primary biliary cholangitis, ursodeoxycholic acid (UDCA) remains the cornerstone of treatment, administered at 13–15 mg/kg/day. Patients who exhibit an inadequate biochemical response after one year—defined by persistent elevation of alkaline phosphatase and/or immunoglobulin M—are candidates for second-line therapy with obeticholic acid or fibrates such as bezafibrate. Emerging agents, including selective peroxisome proliferator-activated receptor (PPAR) agonists, are under active investigation in clinical trials.

Primary sclerosing cholangitis currently lacks FDA-approved pharmacotherapies. Management focuses on surveillance for complications—including dominant strictures, cholangiocarcinoma, and portal hypertension—as well as supportive care such as fat-soluble vitamin supplementation and endoscopic interventions for symptomatic biliary obstruction. Liver transplantation remains the only curative option for end-stage disease.

Accurate diagnosis is critical and relies on integrating clinical presentation, serologic markers (e.g., ANA, SMA, anti-LKM-1 in AIH; AMA in PBC; p-ANCA in PSC), imaging (MRCP or ERCP), and liver biopsy when indicated. Regular monitoring of liver enzymes, immunoglobulins, synthetic function (INR, albumin), and noninvasive fibrosis assessments helps guide therapeutic decisions and detect early decompensation.

Long-term outcomes have improved significantly with timely diagnosis and tailored immunomodulatory or cholestatic therapies. However, adherence to follow-up, vigilant screening for comorbidities—including osteoporosis, metabolic bone disease, and lymphoma—and multidisciplinary care involving hepatologists, radiologists, and transplant specialists remain essential components of optimal management.